NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Alkermes plc (ALKS) Stock Analysis

Alkermes plc (ALKS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

ALKS

$46.10

−$0.78 (−1.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALKS with… →

ALKS Key Statistics

As of Sep 4, 2026
Trading
Open
$46.14
Previous Close
$46.88
Day's Range
45.80–46.93
52-Week Range
25.17–55.67
Volume
1.06M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.26
Valuation
Market Cap
$7.73B
P/E Ratio
124.59
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
25.22
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.96
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.64
EPS (ttm)Profit attributable to each share over the last twelve months.
0.37
Financials (FY)
Revenue (FY)
$1.48B−5.25%
Net Income (FY)
$241.66M−34.16%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
167.76M
1-Year Return
+59.41%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
1.93M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ALKS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+64.76%
2025−2.71%
2024+3.68%
2023+6.16%
2022+12.34%
2021+16.59%
2020−2.21%
2019−30.87%
2018−46.08%
2017−1.53%
2016 (partial year)+17.75%

As of September 4, 2026.

ALKS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.48B$241.66M16.4%
2024$1.56B$367.07M23.6%
2023$1.66B$355.76M21.4%
2022$1.11B−$158.27M−14.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.48B$1.28B$253.96M$241.66M16.4%
2024$1.56B$1.31B$420.64M$367.07M23.6%
2023$1.66B$1.41B$414.12M$355.76M21.4%
2022$1.11B$893.73M−$6.09M−$158.27M−14.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALKS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricALKSDrug Manufacturers - Specialty & Generic medianvs median
P/E124.5919.276.5x the median
P/S ratio4.642.30102% above
Profit margin3.96%−3.14%7.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alkermes plc (ALKS) carries a market capitalisation of $7.73B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 2,050 employees.

The 52-week range on file runs from $25.17 to $55.67. ALKS last closed at $46.10 on September 4, 2026. That is −$0.78 (−1.66%) against the previous close. The latest close sits 83.15% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.48B. Against the prior fiscal year total of $1.56B, that is a change of −5.25%. Net income for the same year was $241.66M. That is −34.16% against the prior fiscal year. The reported profit margin is 3.97%. That is 7.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.37.

Across the 4 fiscal years on file, revenue moves from $1.11B in 2022 to $1.48B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 124.59 times earnings. That is 6.5 times the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 25.22. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.96. The price-to-sales ratio is 4.64. On price-to-sales that is 101.96% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.26. Daily returns over the trailing 10 years annualize to a volatility of 41.22%. The trailing one-year price return is +59.41%. Measured over 10 years, that is +0.22% a year compounded.

Growth & Income

The record shows no dividend for ALKS.

So far in 2026 the price is +64.76%. Across the complete calendar years on file, 2021 returned +16.59% and 2018 returned −46.08%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Alkermes plc (ALKS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alkermes plc ALKS $7.73B 124.6
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Alkermes plc trades at a P/E of 124.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Alkermes plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Visit website →